




Patent Application
Attorney Docket No. PC11066AAKM

04CO
07/11/02

#4

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Hon. Commissioner for Patents, Washington, D.C. 20231 on this 9th day of July, 2002.

By


(Signature of person mailing)
Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael P. DeNinno, et al. :

APPLICATION NO.: 10/099,620 : Examiner:

FILING DATE: March 15, 2002 : Group Art Unit:

TITLE: Compounds for the Treatment of Ischemia :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:


INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to indicate his or her consideration of the foregoing item by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. This information disclosure statement is being submitted before the first office action has been received; therefore, no fee is required. If so fee is required, authorization is hereby provided to charge the required fee to Deposit Account No. 16-1445.

Respectfully submitted,

Date: July 9, 2002


Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871